In conclusion, combined p16 and MTAP immunohistochemistry is a cost-effective surrogate for CDKN2A-MTAP genetic alterations that can be reliably used to detect homozygous deletions and visualize the spatial heterogeneity of the CDKN2A-MTAP gene complex within the same tumor sample. Here, MTAP is linked to neoplasm.